spotlight on migs - glaukos

© 2016 Glaukos Corporation

1

GLAUKOS: TAKING A MIGS COMPANY PUBLIC

Chris Calcaterra, Chief Commercial Officer OIS@ASCRS -- May 5, 2016


2

GLAUKOS INITIAL PUBLIC OFFERING: JUNE 25 2015

MIGS GOES TO WALL STREET


3

• Completed initial public offering on June 25, 2015

• Shares currently trade on New York Stock Exchange under ticker symbol GKOS

NYSE: GKOS


4

The Lead Up

• Founded, built and validated MIGS category over a 15+ year period

• Selected bankers and other key advisors • Worked closely with advisors to prepare offering documents

that described strategy, growth prospects, strengths and risks

• Continually evaluated market conditions to identify optimal IPO timing

• Prepared for more rigorous financial reporting, ongoing public disclosure and compliance with securities laws and regulations

• Expanded board and established new management functions

• Prepared the organization for life as a public company• Required more than a year of intense preparation, while

continuing to run/grow the business


5

• Met with approx. 140 investors to answer questions and explain strategy, potential, competitive strengths and success factors

• Covered 9 cities in 7 days• Strong institutional investor interest:

– First-mover advantage; MIGS pioneer – Novel technology platform that addresses

true unmet need – Demonstrated track record of operational

execution and financial performance– Deep, late-stage product pipeline

The Roadshow


6

Day One

• Sold 6.9 million newly issued shares

• Priced at $18, $3 above initial pricing range

• Shares rose 70% on first trading day

• Raised $113.6 million in net proceeds


7

Wall Street Views on MIGSStrong Support For Glaukos Novel Strategy: iStent® + Cataract Surgery

“The cataract + MIGS procedure takes a patient

who is already having eye surgery and adds in a

layer of clinical efficacy at essentially no

additional risk, no additional cost to the patient,

and no additional inconvenience … Given the

strong incentives supporting MIGS adoption, we

see significant runway for rapid market growth…

“


8

Wall Street Views on MIGSWide Recognition Of Robust Glaukos And iStent® Growth

“We came away from this year’s AAO with a belief that

MIGS will continue to represent a rapidly growing

market … A theme we heard consistently was that the

introduction of iStent has allowed physicians to have

more options in treating patients and has a clear place

in the treatment paradigm.

“


9

Wall Street Views on MIGS

“MIGS is hot. The MIGS space has seen two

acquisitions in the last six months… “

A View That Glaukos’s Success Has Attracted Followers Into The MIGS Space


10

Taking a MIGS Company Public

• Providing higher public profile and awareness of the MIGS space

• Helping to establish market valuations for MIGS technology and opportunity

• Providing capital to invest in continuing development of burgeoning MIGS market/treatment class


11

NYSE TRADERS AWAIT THE OPEN OF GKOS STOCK: JUNE 25, 2015

MIGS GOES TO WALL STREET

spotlight on migs - glaukos

Healthcare